- Home
- RVMD
as 07-26-2024 4:00pm EST
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 6.3B | IPO Year: | 2020 |
| Target Price: | $47.46 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.44 - $48.61 | Next Earning Date: | 08-06-2024 |
| Revenue: | $4,566,000 | Revenue Growth: | -86.89% |
| Revenue Growth (this year): | -45.49% | Revenue Growth (next year): | 24.33% |
Latest Revolution Medicines Inc. News
RVMD Breaking Stock News: Dive into RVMD Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating
MT Newswires
9 days ago
UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating
MT Newswires
10 days ago
Revolution Medicines Insider Sold Shares Worth $1,576,322, According to a Recent SEC Filing
MT Newswires
10 days ago
Needham Adjusts Revolution Medicines Price Target to $62 From $46, Maintains Buy Rating
MT Newswires
10 days ago
HC Wainwright Raises Price Target on Revolution Medicines to $56 From $44, Maintains Buy Rating
MT Newswires
10 days ago
Oppenheimer Adjusts Revolution Medicines Price Target to $55 From $45, Maintains Outperform Rating
MT Newswires
11 days ago
Revolution Medicines Projects 2024 Net Loss of $560 Million to $600 Million; Provides Latest Cancer Drug Study Data
MT Newswires
11 days ago
Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating
Compare RVMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVMD Revolution Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.